NUI Galway leads stem-cell research on diabetic kidney disease, €1.7m in funding for twenty new high-potential research projects announced, Scientific research projects get €1.7million funding boost, Orbsen Therapeutics to take part in €6m liver disease clinical trial, Innovation Awards profile: Orbsen Therapeutics – Stem cell research, The cream of start-ups, college spin-offs and smooth operators. […]

NEW YORK, Sept. 6, 2016 /PRNewswire/ — Dr. Jack Kavanaugh, Chairman of Orbsen Therapeutics (http://www.orbsentherapeutics.com/), announced today the appointment of Larry Couture, PhD, as CEO. “Dr. Couture brings a remarkable background in cellular and genetic therapeutics with industry leading experience in both the scientific and business development of leading edge therapeutics,” said Kavanaugh. He added, “His industry experience at [...]

NEW YORK–(BUSINESS WIRE)–Orbsen Therapeutics (www.orbsentherapeutics.com) breakthrough stromal cell immunotherapy, OBRCEL-M™, developed as part of NEPHSTROM, a European Union Horizon 2020-funded research project coordinated by NUI Galway, has been approved to begin testing in a randomised, double blind, and placebo-controlled European clinical trial to treat diabetic kidney disease. […]